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Cell migrationThe activator protein-1 (AP-1) transcription factor complex plays a crucial role in tumor growth and progression.
However, howAP-1 transcriptional activity is repressed is not fully understood. Here, we show that RNA-binding
protein with multiple splicing 1 (RBPMS1) physically and functionally interacts with AP-1 in vitro and in vivo.
The RNA-recognition motif (RRM) and C-terminus of the RBPMS1 isoforms RBPMS1A and RBPMS1C, but not
RBPMS1B, interacted with cFos, a member of the AP-1 family that dimerizes with cJun to stimulate AP-1 transcrip-
tional activity. RBPMS1 did not associate with Jun proteins. RBPMS1A and RBPMS1C bound to the basic leucine
zipper (bZIP) domain of cFos that mediates dimerization of AP-1 proteins. In addition, RBPMS1A-C interacted
with the transcription factor Smad3, which was shown to interact with cJun and increase AP-1 transcriptional ac-
tivity. RBPMS1 inhibited c-Fos or Smad3-mediated AP-1 transactivation and the expression of AP-1 target genes
known to be the key regulators of cancer growth and progression, including vascular endothelial growth factor
(VEGF) and cyclin D1. Mechanistically, RBPMS1 blocks the formation of the cFos/cJun or Smad3/cJun complex as
well as the recruitment of cFos or Smad3 to the promoters of AP-1 target genes. In cultured cells and a mouse
xenograft model, RBPMS1 inhibited the growth and migration of breast cancer cells through c-Fos or Smad3.
These data suggest that RBPMS1 is a critical repressor of AP-1 signaling and RBPMS1 activation may be a useful
strategy for cancer treatment.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The activator protein-1 (AP-1) transcription factor functions in almost
all areas of eukaryotic cellular behavior, including cancer cell growth,
migration, invasion, and metastasis [1]. The AP-1 complex is composed
of homodimers of Jun family members (cJun, JunB and JunD), heterodi-
mers of Jun and Fos (cFos, FosL1, FosL2, and FosB), or cAMP response
element-binding protein (CREB)/activating transcription factor (ATF)
family members. Fos/Jun heterodimers are more stable and efﬁcient in
driving transcriptional activation than Jun/Jun homodimers [2,3]. UponInterventional Radiology, The
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transcription by binding to their cognate DNA sequences, known as
12-O-tetradecanoylphorbol-13-acetate (TPA) response element, in the
regulatory regions of target genes [4]. As a critical tache of external
signal and cell fate, AP-1 is becoming one of the important targets for
cancer therapy [1].
AP-1 transcriptional activity ismodulated atmultiple levels, including
transcriptional regulation, post-translational modiﬁcations, dimer com-
position, and interactions with many structurally divergent regulatory
proteins. In addition to the interaction between AP-1 family members
that is essential for activation of AP-1 transcriptional activity, association
of the AP-1 family members with other transcription factors or other
ancillary proteins are also critical for control of AP-1 function. For in-
stance, the transcription factors Smads bind to the Jun family of AP-1
and increase AP-1 transcriptional activity [5]. The interaction between
the transcription factor E26 transformation-speciﬁc (ETS) and cJun is
important for AP-1 transactivation. RING domain AP-1 co-activator-1
(RACO1) interacts with cJun and is both necessary and sufﬁcient for
cJun/AP-1 activation [6,7]. SARI (suppressor of AP-1, regulated by IFN)
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AP-1 complex and consequently AP-1-dependent gene expression [8].
Althoughmany proteins have been reported to stimulate AP-1 transcrip-
tional activity through physical interaction, how AP-1 transactivation is
directly repressed remains largely unknown.
RNA-binding protein for multiple splicing (RBPMS) belongs to a
family of RNA-binding proteins characterized by the presence of an
N-terminal RNA-recognition motif (RRM) sequence [9,10]. The
RBPMS family is composed of the members RBPMS1/Hermes and
RBPMS2 [11,12]. Based on GenBank sequence data, there are three
human RBPMS1 isoforms (http://www.ncbi.nlm.nih.gov/gene), which
are designated respectively as RBPMS1A, RBPMS1B and RBPMS1C in
this study. RBPMS1A-C share the same N-terminal RRM domain. The
C-terminus of RBPMS1A-C, however, is different in both length and
composition. Until now, little is known about the biological function
of RBPMSproteins.Wehave previously shown that RBPMS1Cphysically
interacts with Smad2, Smad3 and Smad4 in vitro and in vivo and regu-
lates transforming growth factor-β (TGF-β) signaling [13]. However,
the role of RBPMS1A-C in cancer is unknown.
In this study, we report for the ﬁrst time that RBPMS1A-C repress
AP-1 activity through physical interaction with cFos or Smad3. Mecha-
nistically, RBPMS1A-C block the formation of the cFos/cJun heterodimer
and/or the Smad3/cJun complex as well as the recruitment of cFos
and/or Smad3 to the promoters of AP-1 target genes. RBPMS1A-C inhibit
breast cancer cell growth and migration through regulation of AP-1
signaling.
2. Materials and methods
2.1. Construct generation
Mammalian expression vectors encoding FLAG-, Myc- or HA-fusion
proteins tagged at the amino terminus were constructed by inserting
polymerase chain reaction (PCR)-ampliﬁed fragments into pcDNA3
(Invitrogen). Recombinant lentivirus vectors for the three RBPMS1
isoforms were made by inserting PCR-ampliﬁed fragments into
pCDH-EF1-MCST2A-puro (System Biosciences). Plasmids encoding
glutathione-S-transferase (GST) or green ﬂuorescent protein (GFP)
fusion proteins were generated by cloning PCR-ampliﬁed sequences
into pGEX-KG (Amersham Pharmacia Biotech) or pEGFP-C1 (Becton
Dickinson, USA), respectively. The open reading frames of RBPMS1A,
RBPMS1B and RBPMS1C were ampliﬁed by PCR according to the
GenBank accession numbers: NM_001008710 (RBPMS1A), NM_
001008711 (RBPMS1B) andNM_001008712 (RBPMS1C). The cDNA tar-
get sequences of siRNAs for RBPMS1A-C, cFos, cJun, and Smad3 are listed
in Supplemental Table 1A. siRNAs were cloned into pSilencer2.1-U6neo
(Ambion) and pSIH-H1-puro (System Biosciences) according to the
manufacturers' protocols.
2.2. Cell culture, transfection, and luciferase reporter assay
HEK293T embryonic kidney cells and MCF7 and ZR75-1 breast
cancer cells were routinely cultured in DMEM (Invitrogen) containing
10% FBS (Hyclone). Lipofectamine 2000 reagent was used for transfec-
tions following the manufacturer's protocol (Invitrogen). Lentiviruses
were produced by cotransfection of HEK293T cells with recombinant
lentivirus vectors and pPACK Packaging Plasmid Mix (System Biosci-
ences) using Megatran reagent (Origene). Lentiviruses were collected
48 h after transfection and added to the medium of target cells with
8 μg/ml polybrene (Sigma-Aldrich). Stable cell lines were selected in
0.4–1.0 μg/ml puromycin. Pooled clones or individual clones were
screened by standard immunoblot protocols and produced similar re-
sults. Luciferase reporter assayswere performed asdescribedpreviously
[14]. In this study, we used the AP-1-Luc reporter (Clontech), which
contains the luciferase gene driven by the thymidine kinase promoterand an AP-1-dependent enhancer element. All experiments were re-
peated at least three times with similar results.
2.3. Real-time reverse-transcription-PCR (RT-PCR)
Total RNAwas isolated using TRIzol Reagent (Invitrogen) and reverse
transcribed using SuperScript II Reverse Transcriptase (Invitrogen). Real-
time PCR was performed with the primers listed in Supplemental
Table 1B. Gene expression levels were normalized to GAPDH and the
fold change of target gene was calculated using the 2−ΔΔCt method.
2.4. GST pull-down assay
GST fusion proteins were expressed in pGEX-KG and puriﬁed by
glutathione-Sepharose 4B beads according to the manufacturer's in-
structions (Amersham Pharmacia Biotech). Myc-tagged cFos was
transfected into HEK293T cells and the transfected cells were harvested
48 h after transfection. Cellular lysate containing the cFoswas incubated
with different GST fusion proteins bound to glutathione-Sepharose
beads in 0.5ml of the binding buffer at 4 °C for 4 h. The beads were pre-
cipitated, washed four times with the binding buffer, eluted by boiling
in SDS sample buffer, and analyzed by SDS-PAGE.
2.5. Co-immunoprecipitation
For transfection-based co-immunoprecipitation assays, HEK293T
cells were transfected with the indicated plasmids using Lipofectamine
2000 (Invitrogen), lysed in 0.5 ml lysis buffer, and immunoprecipitated
with anti-FLAG or anti-Myc agarose beads (Sigma-Aldrich) as previ-
ously described [15]. The beads were washed four times with the
lysis buffer, and eluted in SDS sample buffer. The eluted proteins were
separated by SDS-PAGE, followed by Western blot with anti-GFP
(Sigma-Aldrich), anti-FLAG (Sigma-Aldrich), or anti-HA (Sigma-
Aldrich) antibody.
For detecting interaction of endogenous cFos with RBPMS1A-C,
ZR75-1 cells cultured in 10-cm dishes were collected and lysed in
0.5 ml lysis buffer and immunoprecipitated with anti-RBPMS1
(Santa Cruz Biotechnology) or control serum (Santa Cruz Biotech-
nology). After extensive washing, the immunoprecipitates were
resolved by SDS-PAGE, followed by Western blot analysis using
anti-RBPMS1 and anti-cFos (Santa Cruz Biotechnology). The anti-
RBPMS1 antibody could recognize the common region (N-terminus)
of RBPMS1A, RBPMS1B and RBPMS1C according to the manufacturer's
instructions.
2.6. Immunoﬂuorescence
Immunoﬂuorescence was performed as previously described [16].
Brieﬂy, cells grown on glass coverslips were ﬁxed, permeabilized, and
blocked in normal goat serum. The coverslips were then incubated
with rabbit anti-RBPMS1 and mouse anti-cFos, followed by incubation
with corresponding secondary antibodies. Nuclei were counterstained
withDAPI. Confocal imageswere collectedusing aRadiance2100 confocal
microscope (Bio-Rad).
2.7. Chromatin immunoprecipitation assay (ChIP)
ChIP assays were performed as described previously [15] using
anti-cFos (Santa Cruz Biotechnology) or anti-Smad3 (Millipore). The
primers used for ChIP are listed in Supplemental Table 1C.
2.8. Enzyme-linked immunosorbent assay (ELISA) for human VEGF165
analysis
Cells were seeded into 12-well plates. Forty eight hours later, cell
supernatant was harvested to determine the concentration of vascular
3J. Fu et al. / Biochimica et Biophysica Acta 1853 (2015) 1–13endothelial growth factor (VEGF) using human VEGF kit (R&D systems)
according to the manufacturer's instructions.2.9. Cell proliferation and migration assays
Cell proliferation was assessed using Cell Counting Kit-8 (CCK-8)
according to the manufacturer's instructions (Dojindo). For Transwell
migration assays [17], harvested cells (105 cells) were replated onto
the upper chamber of a Transwell ﬁlter with 8 μM pores (Costar), and
the upper chamber was placed in DMEM containing 2% serum and the
lower chamber 12% serum. After 16 h, unmigrated cells were removed
from the upper chamber with a cotton swab. The remaining cells that
have migrated through the membrane were ﬁxed, stained with 0.1%
crystal violet for 10 min at room temperature, and photographedA
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Fig. 1. RBPMS1A-Cmodulate AP-1 transcriptional activity. (A) Luciferase reporter assays in ZR7
HA-tagged RBPMS1A-C, and FLAG-tagged cFos and cJun. *P b 0.05 versus empty vector (lanes 3
HEK293T (right panel) cells cotransfectedwith AP-1-Luc and HA-tagged RBPMS1A-Cwith or w
lanes) or with PMA (even number lanes). (C) Luciferase reporter assays in ZR75-1 (left panel)
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panel) cotransfectedwith AP-1-Luc, RBPMS1 siRNA, FLAG-tagged cFos and cJun, and siRNA-resis
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reader.2.10. Animal experiments
Animal studieswere approvedby the Institutional Animal Care Com-
mittee of Beijing Institute of Biotechnology. Ten million tumor cells were
injected into the abdominal mammary fat pad of 6-week-old female
nude mice. Tumor growth was monitored by caliper measurements.
Tumor volume was calculated according to the following formula:
volume = (longest diameter × shortest diameter2) / 2. The portions of
excised tumors were collected and frozen in liquid nitrogen or ﬁxed in
4% paraformaldehyde for further study [18].GAPDH
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Fig. 1 (continued).
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Immunohistochemistry of formalin-ﬁxed parafﬁn-embedded
sampleswas performed as described previously [15]. For CD31 staining,
tumor sections were incubated with an anti-CD31 antibody (Bethyl
Laboratories). For the quantiﬁcation of microvessel density, pictures
from eight areas in each group were taken using an OLYMPUS BX51
and the vessel number was manually counted.
2.12. Statistical analysis
Differences between variables were assessed by 2-tailed Student's t
test. Statistical calculations were performed using SPSS 13.0. P values
of less than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. RBPMS1A-C regulate AP-1 transcriptional activity in PMA-independent
manner
We ﬁrst determined the expression of endogenous RBPMS1A,
RBPMS1B, and RBPMS1C at both mRNA and protein levels in breast
cancer cell lines. RT-PCR analyses showed that the coding regions
of RBPMS1A, RBPMS1B and RBPMS1C were successfully ampliﬁedin MCF7, BT474, MDA-MB-231, and ZR75-1 cells (Supplemental
Fig. 1), with subsequent conﬁrmation by DNA sequencing (data not
shown). For protein expression analysis of RBPMS1 variants, the
speciﬁcity of an anti-RBPMS1 antibody, which could recognize
RBPMS1A-C, was ﬁrst validated by Western blot with anti-RBPMS1
and anti-HA as well as immunoﬂuorescence staining with RBPMS1
siRNA, which targeted RBPMS1A-C (Supplemental Fig. 2). According
to the predictedmolecular weights of endogenous RBPMS1A (196 aa,
23.5 kDa), endogenous RBPMS1B (204 aa, 24.5 kDa) and endoge-
nous RBPMS1C (219 aa, 26.3 kDa), MDA-MB-231, ZR75-1, MCF7,
T47D, SKBR3, and BT474 breast cancer cells as well as HEK293T em-
bryonic kidney cells expressed endogenous RBPMS1A-C proteins,
usually with RBPMS1C as the predominant isoform (Supplemental
Fig. 2B). Since the C-terminus of RBPMS1A-C that is different among
them is a little short, targeting their different regions by siRNAs seemed
to be technically difﬁcult (data not shown). Thus, we used RBPMS1
siRNA,which targeted the common region of the three RBPMS1 isoforms,
to knockdown endogenous RBPMS1A-C expression (Supplemental
Fig. 2C).
To deﬁne the potential role of RBPMS1A-C in tumorigenesis, we in-
vestigated whether RBPMS1A-C regulate AP-1 signaling. In ZR75-1
and HEK293T cells, AP-1 luciferase reporter construct was transfected
to indicate the AP-1 activity caused by the endogenous or exogenous
cFos/cJun dimer. Results showed that overexpression of RBPMS1A-C
B
FLAG-FosL1
FLAG-FosL2
Empty vector
IP˖FLAG
IB˖FLAG
Input
IB˖FLAG
IP˖FLAG
IB˖FLAG
Input
IB˖HA
IP˖FLAG
IB˖HA
FLAG-FosB
FLAG-JunB
FLAG-JunD
FLAG-cFos
FLAG-cJun
Input
IB˖FLAG
Input
IB˖HA
HA-RBPMS1A +     +    +     +      +      +      +    +
IP˖FLAG
IB˖HA
+
+
+
+
+
+
+
+
IB: RBPMS1
IB: cFos
Light chain
D
A
FLAG-FosL1
FLAG-FosL2
Empty vector
FLAG-FosB
FLAG-JunB
FLAG-JunD
FLAG-cFos
FLAG-cJun
HA-RBPMS1B +     +    +     +      +      +      +    +
+
+
+
+
+
+
+
+
IPC
FLAG-FosL1
FLAG-FosL2
Empty vector
IP˖FLAG
IB˖FLAG
FLAG-FosB
FLAG-JunB
FLAG-JunD
FLAG-cFos
FLAG-cJun
Input
IB˖FLAG
Input
IB˖HA
HA-RBPMS1C +     +    +     +      +      +      +     +
IP˖FLAG
IB˖HA
+
+
+
+
+
+
+
+ E
IB: Myc (cFos)
IB: GST
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served in MCF7 cells (Supplemental Fig. 3A).
Based on our ﬁnding that RBPMS1A-C can regulate AP-1 transcrip-
tional activity, we determined the effect of phorbol 13-myristate 12-
acetate (PMA), a commonly used stimulator of AP-1 activity [1–4], on
RBPMS1A-C modulation of AP-1 transactivation. As expected, PMA
could efﬁciently induce AP-1 transcriptional activity (Fig. 1B). In the
absence or presence of PMA, RBPMS1A-C inhibited the transcriptional
activity of AP-1 with similar magnitude (Fig. 1B, C and Supplemental
Fig. 3B), indicating that RBPMS1A-C regulates AP-1 transcriptional
activity in PMA-independent manner. However, we cannot exclude
the possibility that RBPMS1A-C modulate AP-1 activity through other
stimuli, because AP-1 activity was shown to be induced by many
other stimuli, including growth factors and cytokines [19], which may
exist in culture medium. The reason why the fold induction of AP-1
activity by cJun–cFos overexpression or PMA treatmentwith or without
RBPMS1A-C is similar might be that neither did RBPMS1A-C change the
expression of cJun and cFos nor did RBPMS1A-C alter PMA-inducedphosphorylation of cJun on serine 63, which plays an important role in
the regulation of AP-1 activity [20] (Fig. 1A and B).
Since cFos and cJun are important members of the AP-1 transcription
factor complex, we determine whether inhibition of AP-1 transcriptional
activity by RBPMS1A-C was cFos/cJun dependent. Knockdown of
cFos/cJun with cFos and cJun siRNAs dramatically decreased AP-1
transactivation (Fig. 1C). Importantly, knockdown of cFos/cJun
abolished the ability of RBPMS1A-C to repress AP-1 transcriptional
activity. However, RBPMS1A-C still inhibited AP-1 activity in cFos
knockdown cells, albeit to a lesser extent (Supplemental Fig. 3C
and D). These data suggest that cJun is required for RBPMS1A-Cmod-
ulation of AP-1 transcriptional activity.
To investigate the physiological role of RBPMS1A-C in AP-1 activity
regulation, we knocked-down endogenous RBPMS1A-C expression by
RBPMS1 siRNA. Consistent with the overexpression results, RBPMS1A-C
knockdown enhanced AP-1 transcriptional activity in ZR75-1 and
HEK293T cells (Fig. 1D). These effects could be rescued by RBPMS1A-C
reexpression in the RBPMS1A-C knockdown cells.
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The interaction with ancillary proteins is one of the most common
ways to regulate AP-1 transcriptional activity. To elucidate the probable
mechanism of RBPMS1A-C regulating the AP-1, we ﬁrst attempted todetermine whether RBPMS1A-C interact with Fos and Jun subfamily
members. Coimmunoprecipitation assays showed that HA-tagged
RBPMS1A and RBPMS1C interacted with cFos, FosB, and FosL1, but not
with FosL2 or any of the Jun familymembers (Fig. 2, A–C). Unexpectedly,
HA-RBPMS1B failed to coimmunoprecipitate any member of the Fos
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RBPMS1A, RBPMS1B, or RBPMS1C. Western blot showed the expression of cJun, Smad3 and RBPMS1A-C with the indicated antibodies. Data shown are means ± SD of three in-
dependent experiments. *P b 0.05, **P b 0.01 versus empty vector; $P b 0.05 versus FLAG-tagged Smad3; #P b 0.05 versus Myc-tagged cJun; &P b 0.05 versus Myc-tagged cJun plus
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of RBPMS1A-C and cFos proteins was conﬁrmed by endogenous
coimmunoprecipitation assays in ZR75-1 breast cancer cells (Fig. 2D).
The in vivo interaction of RBPMS1A-C with cFos was unlikely to be
mediated by RNA, as it was not affected by RNase treatment prior to im-
munoprecipitation (data not shown). Consistent with the results of
coimmunoprecipitation assays, GST pull-down experiments demonstrat-
ed that RBPMS1A and RBPMS1C, but not RBPMS1B, interacted with cFos
in vitro (Fig. 2E). In addition, RBPMS1A/C colocalized with cFos (Supple-
mental Fig. 4A). The observation that RBPMS1A and RBPMS1C, but not
RBPMS1B, interact with cFos might be due to different C-terminus of
RBPMS1A-C (Supplemental Fig. 4B). Taken together, these data indicate
that RBPMS1A and RBPMS1C interact with cFos both in vitro and in vivo.
3.3. Mapping of the cFos and RBPMS1A/C interaction regions
To deﬁne the regions of RBPMS1A/C required for its interaction
with cFos, different RBPMS1A and RBPMS1C mutants with GFP tag
were cotransfected with FLAG-cFos, and coimmunoprecipitationexperiments were performed in HEK293T cells. RBPMS1 (1–100)
containing the RRM domain (for RBPMS1A-C due to identical amino
acid sequence among them), RBPMS1A (161–196) containing the
C-terminus different from the other two RBPMS1 isoforms, RBPMS1A
(25–196) containing the RRM domain, and RBPMS1 (Δ25–100) lacking
the RRM domain but containing the C-terminus bound to c-Fos, while
RBPMS1 (101–160) and RBPMS1 (1–24), both of which lack the RRM
domain and the C-terminus, did not (Fig. 3A), suggesting that the com-
monRRMdomain and the unique C-terminus of RBPMS1A are sufﬁcient
to interact with cFos. Similar results were obtained with RBPMS1C
(Fig. 3B). However, the unique C-terminus of RBPMS1B failed to bind
to cFos (Supplemental Fig. 4C).
To deﬁne the region of cFos that is important for RBPMS1A/C
interaction, a series of deletion mutants of cFos were used for
coimmunoprecipitation. cFos (147–185) containing the bZIP domain
speciﬁcally bound to RBPMS1A (Fig. 3C) or RBPMS1C (Fig. 3D), whereas
cFos (1–147) containing the N-terminal transactivation domain and
cFos (185–380) containing the C-terminal transactivation domain and
inhibitory domain did not.
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activation
Smad3 was shown to interact with cJun and stimulate AP-1 tran-
scriptional activity independent of Smad DNA-binding activity [5]. We
have previously shown that RBPMS1C associates with Smad3 and the
same N-terminal RRM domain [RBPMS1C(1-100)] shared by RBPMS1A
and RBPMS1B contributes to this association [8]. The fact that RBPMS1B
does not interact with cFos but it regulates AP-1 activity raises the
possibility that RBPMS1B may affect AP-1 activity through interaction
with Smad3. On the other hand, it is possible that RBPMS1A and
RBPMS1C can also modulate AP-1 activity at least partly through
Smad3. Thus, we tested whether RBPMS1A and RBPMS1B interact
with Smad3. Indeed, like RBPMS1C, RBPMS1A and RBPMS1B interacted
with Smad3 (Fig. 4A). As previously reported, Smad3 increased the AP-1
reporter activity caused by endogenous or exogenous cJun (Fig. 4B).
Importantly, RBPMS1A-C repressed Smad3-mediated AP-1 activa-
tion (Fig. 4B). Knockdown of Smad3 attenuated the ability of
RBPMS1A and RBPMS1C to inhibit AP-1 transcriptional activity and
abolished the ability of RBPMS1B to repress AP-1 activity (Fig. 4C),
suggesting that Smad3 is required for the regulation of AP-1 trans-
activation by RBPMS1B and critical for this regulation by RBPMS1A
and RBPMS1B.3.5. RBPMS1A-C regulates the expression of AP-1 target genes
To corroborate the results of the luciferase reporter assays, the effect
of RBPMS1A-C on the expression of AP-1 target genes was determined.
Knockdown of RBPMS1A-C in ZR75-1 cells increased the transcription
of AP-1 responsive genes known to have important functions in cellcycle regulation, angiogenesis and metastasis, including the VEGF iso-
forms VEGF121 and VEGF165, urokinase-type plasminogen activator
(uPA), cyclin D1 (CCND1), and cluster of differentiation 44 (CD44)
(Fig. 5A, B). RBPMS1A-C knockdown also enhanced the expression
of cyclin D1 and VEGF165 at protein levels (Fig. 5B and C). Consistent
with the results of regulation of AP-1 target genes by RBPMS1A-C
knockdown, overexpression of RBPMS1A-C reduced the expression
of cyclin D1 and VEGF165 proteins (Fig. 5D and E). Moreover, knock-
down c-Fos or Smad3 greatly affected or abolished the ability of
RBPMS1A-C to regulate the expression of cyclin D1 and VEGF165
(Fig. 5D and E).
3.6. RBPMS1A-C regulate the dimerization of cFos/cJun and/or the formation
of the Smad3–cJun complex
Dimerization is a regulatory mechanism of controlling transcription
factor activity. Upon dimerization, transcription factors bind to promoter
sequences of target genes. cFos/cJun heterodimerization is thought to be
critical for AP-1 transcriptional activity. The bZIP domain mediates
the interaction of AP-1 family members. Based on the ﬁndings that
AP-1 transcriptional activity mediated by cFos/cJun is inhibited by
RBPMS1A/C, and cFos interacts with RBPMS1A or RBPMS1C via bZIP
domain, we hypothesized that RBPMS1A or RBPMS1C might repress AP-
1 transcriptional activity by interfering with the formation of cFos/cJun
heterodimer. Indeed, overexpression of RBPMS1A or RBPMS1C at-
tenuated the cFos/cJun heterodimer formation in a dose-dependent
manner (Fig. 6A and B), whereas overexpression of the mutant
RBPMS1 (101–160) that contains identical amino acid sequences
among RBPMS1A-C and lacks cFos/Smad3 binding site did not (Supple-
mental Fig. 5A). As expected, cJun did not interact with RBPMS1A,
excluding the possibility that RBPMS1A, cJun and cFos form a tertiary
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cJun, Myc-tagged cFos, and increasing amounts of GFP-tagged RBPMS1A (A) or RBPMS1C (B), as indicated. Co-IP was performed using anti-Myc or anti-FLAG, followed by immunoblot
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9J. Fu et al. / Biochimica et Biophysica Acta 1853 (2015) 1–13complex (Fig. 6A). Moreover, reduction of endogenous RBPMS1A-C
with RBPMS1 siRNA enhanced the interaction between cFos and cJun
(Fig. 6C).
Smad3 has been reported to act as a coactivator for AP-1 through
its interaction with cJun (5). Since RBPMS1A-C interact with Smad3,
but not cJun, and inhibit Smad3-mediated AP-1 activation, we tested
whether RBPMS1A-C competes with cJun for binding Smad3.Coimmunoprecipitation experiments showed that overexpression
of RBPMS1A-C, but not the RBPMS1 (101–160) mutant, inhibited
the interaction between Smad3 and cJun (Fig. 6D and Supplemental
Fig. 5B). In contrast, knockdown of RBPMS1A-C enhanced the inter-
action of Smad3 with cJun (Fig. 6E). Moreover, unlike wild-type
RBPMS1A, the RBPMS1 (101–160) mutant that does not inhibit the
formation of the cFos/cJun or Smad3/cJun complex also did not suppress
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Fig. 7. RBPMS1A-C inhibit the growth andmigration of breast cancer cells in vitro. (A, B) Cell growth assays in ZR75-1 cells cotransfectedwithHA-tagged RBPMS1A-C and cFos siRNA (A) or
Smad3 siRNA (B). Cell viability was assessed at the indicated times. Data shown are mean ± SD of triplicate measurements. *P b 0.05 versus empty vector plus control siRNA on day 4.
(C) Cell growth assays in ZR75-1 cells transfected with RBPMS1 siRNA or RBPMS1 siRNA plus siRNA-resistant RBPMS1A-C (RBPMS1A-C-R). Cells were analyzed as in (A) and (B).
*P b 0.05 versus control siRNA on day 4. (D) Cells were transfected as in (A) and (B). Migration transwell assays were performed for 16 h. Scale bar, 100 μm. *P b 0.05 versus empty vector
plus control siRNA. (E) ZR75-1 cells were transfectedwith RBPMS1 siRNA or RBPMS1 siRNA plus siRNA-resistant RBPMS1A-C, and were analyzed as in (C). *P b 0.05 versus control siRNA.
10 J. Fu et al. / Biochimica et Biophysica Acta 1853 (2015) 1–13AP-1 transcriptional activity (Supplementary Fig. 5C). It should be noted
that wild-type RBPMS1A and the mutant expressed at comparable
levels. Interestingly, like RBPMS1C, RBPMS1C (101–219) could stillinhibit AP-1 transactivation, albeit to a lesser extent (Supplemental
Fig. 5D). This might be due to the interaction of RBPMS1C (101–219)
with cFos (Supplemental Fig. 5E).
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Fig. 8. RBPMS1A-C reduce breast cancer cell growth in vivo. (A) Volume of xenograft
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AP-1 target genes
Based on our ﬁndings that RBPMS1A-C block the formation of cJun-
cFos and Smad3-cJun complexes, we examined whether RBPMS1A-C
affect the recruitment of c-Fos and/or Smad3 to the promoters of AP-1
target genes. As expected, cFos and Smad3 could be recruited to cyclin
D1 and VEGF promoters but not to an unrelated β-actin promoter
(Fig. 6F). Importantly, consistent with the results of RBPMS1A-C modu-
lation of AP-1 transcriptional activity, overexpression of RBPMS1A-C
decreased cFos and/or Smad3 promoter occupancy (Fig. 6F), whereas
knockdown of RBPMS1A-C enhanced cFos and/or Smad3 promoter
occupancy (Fig. 6G).3.8. RBPMS1A-C inhibit breast cancer cell growth in vitro and in vivo
Since RBPMS1A-C inhibit AP-1 activity, the effects of RBPMS1A-C on
breast cancer cell growth and migration were examined. Cell growth
and migration ability were determined in ZR75-1 cells transiently
transfected with RBPMS1A-C or RBPMS1 (101–160). Overexpression
of RBPMS1A-C, inhibited ZR75-1 cell growth (Fig. 7, A and B), whereas
knockdown of endogenous RBPMS1A-C increased the growth of ZR75-1
cells (Fig. 7C). Such effect could be rescued by RBPMS1A-C reexpression
in the RBPMS1A-C knockdown cells (Fig. 7C). Knockdown of cFos or
Smad3 abolished the ability of RBPMS1A-C to regulate the growth of
ZR75-1 cells (Fig. 7A and B). Transwell experiments showed that overex-
pression of RBPMS1A-C decreased ZR75-1 cell migration (Fig. 7D), while
knockdown of RBPMS1A-C increased the migration of ZR75-1 cells
(Fig. 7E). Again, the observed knockdown effect was rescued by
RBPMS1A-C reexpression. Knockdown of cFos or Smad3 greatly affected
or abolished the ability of RBPMS1A-C to modulate the migration of
ZR75-1 cells (Fig. 7D). Furthermore, all mice inoculated with ZR75-1
cells expressing RBPMS1 siRNA grew much faster than those expressing
control siRNAorwithout siRNA (Fig. 8A). Since estrogen,which promotes
the growth of estrogen receptor α-positive ZR75-1 cells, was not used in
the animal experiments, the tumorswith control siRNA orwithout siRNA
grew very slowly. The tumors in mice inoculated with ZR75-1 cells
expressing RBPMS1 siRNA had increased mRNA levels of VEGF121,
VEGF165, uPA, CCND1, and CD44, which was accordant with the in vitro
experiments (Fig. 8B). Immunohistochemical staining with an antibody
against CD31, a vascular marker, showed that the number of blood
vessels increased when RBPMS1A-C was knocked down (Fig. 8C).
4. Discussion
In this study, we have identiﬁed a novel role for RBPMS1A-C in cancer
cell proliferation and migration. RBPMS1A-C exert its function through
regulation of cFos and Smad3-mediated AP-1 signaling (Fig. 9). In breast
cancer cells, the AP-1 proteins have been identiﬁed as critical regulators
of transformation, growth and invasion [4,21]. AP-1 proteins are dif-
ferentially expressed in human breast tumors. For instance, cFos are
overexpressed in N95% of ductal breast carcinoma tissue samples
contrasting with very low or undetectable levels in normal tissue [22].
Increased cFos protein expression is associated with poor prognosis in
breast cancer [23]. Reduction of cFos expression is able to reduce the
proliferation and invasiveness of breast cancer cells [24,25]. cJun corre-
lates with invasive properties of aggressive breast cancer [26,27]. Over-
expression of cJun in breast cancer cells increases migration and
invasion in vitro and tumor formation in vivo [28,29]. In contrast, the
cells expressing dominant-negative cJun fail to invade. cJun expression
also associateswith increasedmicrovessel density [30]. Smad3has been
shown to interact with cJun and enhance AP-1 transcriptional activi-
ty [5]. Although Smad3 inhibits cell growth, its expression in breast
cancer cells enhances lung or bone metastasis [31,32]. The fact that
RBPMS1A-C inhibit the formation of the cFos–cJun and Smad3–cJun
complex suggests that RBPMS1A-C play an important role in the devel-
opment and progression of breast cancer at least in part through the
regulation of AP-1 signaling.
Although cFoswas shown to be responsible for RBPMS1A-Cmodula-
tion of AP-1 activity, RBPMS1A-C still inhibit AP-1 activity in cFos knock-
down cells, albeit to a lesser extent. Since RBPMS1A and RBPMS1C can
interact with FosB and FosL1, and cJun can form heterodimers with
FosB and FosL1 besides cFos [1–4], it is conceivable that, in cFos knock-
down cells, RBPMS1A and RBPMS1C may repress AP-1 activity through
cJun-FosB and cJun-FosL1. Since Smad3 can associate with the cJun–
cFos complex and cJun can interact with FosB and FosL1, it is possible
that Smad3 may form a complex with cJun–FosB or cJun–FosL1. The
fact that RBPMS1A-C inhibit Smad3-mediated AP-1 activation suggests
that, in cFos knockdown cells, RBPMS1A-C may also repress Smad3-
mediated AP-1 activation via cJun–FosB and cJun–FosL1. Whether
Fig. 9. Proposed model for RBPMS1A-C modulation of AP-1 activity. Various RBPMS1 isoforms differentially block the formation of the cJun–cFos or cJun–Smad3 complex through inter-
action with cFos or Smad3, resulting in reduced recruitment of cFos or Smad3 to the promoters of AP-1 target genes. In turn, RBPMS1A-C decrease the transcription of AP-1 target genes,
resulting in reduced breast cancer cell proliferation and migration.
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requires further investigation.
The AP-1 transcription factor directly regulates transcription of
many genes known to have important roles in cell growth, migration,
invasion, and metastasis, including VEGF, cyclin D1, CD44, and uPA [4,
21]. VEGF is a key regulator of angiogenesis that is essential for tumor
growth and metastasis [33,34]. Tumors cannot grow beyond a limited
sizewithout an adequate blood supply. However, cancer cells that over-
express VEGF can grow continuously and metastasize in vivo. VEGF
overexpression has been shown in many types of cancer and indicates
a poor prognosis for cancer patients. The discovery of VEGF as the key
regulator of tumor angiogenesis has enabled the speciﬁc and successful
repression of angiogenesis in experimental and clinical studies. Different
agents including antibodies, peptides and small molecules have been
demonstrated to repress VEGF and its proangiogenic functions [35,36].
Some of them were approved to clinical applications. Cyclin D1 is a key
cell cycle regulator of the G1 to S phase progression [37,38]. Overexpres-
sion and ampliﬁcation of cyclin D1 are common in human cancers of
epithelial cell origin. Increased cyclin D1 is often associated with poor
prognosis.Many in vitro and in vivo studies have shown that overexpres-
sion of cyclin D1 promotes tumor cell growth and confers resistance to
some drugs. Our observations that RBPMS1A-C regulate VEGF and cyclin
D1 at both mRNA and protein levels and that it modulates microvessel
density suggest an important role for RBPMS1A-C in tumor growth and
progression. It will be interesting to investigate whether RBPMS1A-C
expression is associated with prognosis and drug resistance.
Up to now, the biological function of RBPMS1A-C is still largely un-
known. Most previously reported studies were performed using one
form of Xenopus RBPMS1 gene (also called Hermes) [9,10]. There are
three different human RBPMS1 variants based on GenBank sequence
data. Thus, we used the three RBPMS1 isoforms to systematically inves-
tigate their role in cancer. RBPMS1C was shown to be the predominant
isoform in breast cancer cell linesweused and regulates TGF-β signaling
through its interaction with Smads in our previous study [13]. In this
study, we showed that RBPMS1A and RBPMS1C associate with cFos
via the RRM domain and the last C-terminus that is different among
RBPMS1A-C. Unexpectedly, RBPMS1B does not bind to cFos although it
contains the same RRM domain as RBPMS1A and RBPMS1C, suggesting
that the last C-terminus of RBPMS1B may hinder the interaction of its
RRM domain with cFos.
The RRM, also known as the RNA-binding domain (RBD) or ribonu-
cleoprotein domain (RNP), is one of the most abundant protein domains,
and is necessary and sufﬁcient for binding RNA molecules with a wide
range of speciﬁcities and afﬁnities [39]. In humans, approximately 500
proteins containing at least one RRM have been identiﬁed. Eukaryotic
RRM proteins are present in all post-transcriptional events: pre-mRNAprocessing, splicing, alternative splicing, RNA editing, mRNA export,
mRNA stability, pre-rRNA complex formation, translational regulation,
and protein degradation. Whether RBPMS1A-C participates in these
events remains unclear.We showed that the RRMof RBPMS1A-Cwas suf-
ﬁcient for binding cFos in this study and Smad in previous study [13], and
RNA was not required for these interactions. Our results suggest that the
RRM of RBPMS1A-C is involved in direct protein–protein interaction as
well as transcriptional regulation of gene expression. Dowhan et al. also
demonstrated that steroid hormone receptor-regulated transcription
and pre-mRNA splicing can be directly linked through dual function coac-
tivator molecules such as U2AF65-related proteins CAPERα and CAPERβ
[40]. Whether RBPMS1A-C couple transcription and pre-mRNA process-
ing to modulate gene expression remains to be investigated.
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